Next Article in Journal
Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact
Next Article in Special Issue
TNF-α Inhibitors Decrease Classical CD14hiCD16− Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis
Previous Article in Journal
Cognitive Impairment and Celiac Disease: Is Transcranial Magnetic Stimulation a Trait d’Union between Gut and Brain?
Previous Article in Special Issue
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview

Anti-TNF Therapy in Crohn’s Disease

1
Robin Phillips Fistula Research Unit, St Mark’s Hospital and Academic Institute, Harrow HA1 3UK, UK
2
Department of Surgery and Cancer, Imperial College, London, South Kensington Campus, London SW7 2AZ, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(8), 2244; https://doi.org/10.3390/ijms19082244
Received: 26 May 2018 / Revised: 4 July 2018 / Accepted: 7 July 2018 / Published: 31 July 2018
(This article belongs to the Special Issue Tumor Necrosis Factor (TNF))
  |  
PDF [392 KB, uploaded 1 August 2018]

Abstract

Crohn’s disease (CD) accounts for a variety of clinical manifestations or phenotypes that stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is increasing including younger or childhood-onset of disease. The natural history of Crohn’s disease is characterized by a remitting and relapsing course that progresses to complications and surgery in most patients. The goals of treatment are to achieve clinical and endoscopic remission, to avoid disease progression and minimise surgical resections. Medical treatment usually features antibiotics, corticosteroids, immunomodulators (thiopurines, methotrexate). Anti-TNF (tumour necrosis factor) therapy was approved for use in Crohn’s disease in 1998, and has changed the paradigm of treatment, leading to improved rates of response and remission in patients. There are significant considerations that need to be borne in mind, when treating patients including immunogenicity, safety profile and duration of treatment. View Full-Text
Keywords: anti-TNF; Crohn’s disease; medical treatment anti-TNF; Crohn’s disease; medical treatment
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Adegbola, S.O.; Sahnan, K.; Warusavitarne, J.; Hart, A.; Tozer, P. Anti-TNF Therapy in Crohn’s Disease. Int. J. Mol. Sci. 2018, 19, 2244.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top